Carrick NewsroomPress Releases

Informa Pharma Intelligence’s Citeline Api Works With Saama To Deliver Unprecedented Insight Into Clinical Trials

London (February 12, 2018) – Today, Citeline, part of Informa Pharma Intelligence’s suite of pharmaceutical, medtech and biomedical research and analysis solutions, and Saama Technologies, Inc., a leading clinical analytics company, announced a partnership to integrate Citeline’s application programming interfaces (APIs) with Saama’s artificial intelligence and deep learning solutions.

This is a strategic effort to bridge global clinical data and real-world data to improve both planning for and conducting clinical trials. Joint customers will get unparalleled insight into robust clinical trial intelligence with greater efficiency than before.

Saama is integrating with Citeline’s APIs, including Trialtrove and Sitetrove, which provide users with the ability to go even deeper with search criteria and make better, more well-informed decisions, gain competitive advantage, and optimize ROI for their clinical trials. Combined with Saama’s real-world analytics, mutual customers will have smarter, more streamlined and successful clinical trials.

“This partnership represents a great use case for Citeline’s newly released API’s,” said Jason Tse, Head of Strategic Partnerships at Informa Pharma Intelligence. We’re continuing to drive innovative products alongside our partners and bridge real-world data with our clinical trial information, tackling a growing unmet need in our industry. Through this partnership, our joint customers will be able to overcome clinical development challenges, gain industry insights, and optimize trial success through multiple points of triangulation.”

“The partnership between Citeline’s expert clinical trial data and Saama’s award-winning AI-enabled technologies, which leverage both structured and unstructured real-world data, represents the next phase of intelligent clinical trial planning and execution,” said Luke Stewart, Director of Product Management at Saama.

Attendees at this week’s 2018 Summit for Clinical Ops Executives (SCOPE) meeting in Orlando should visit Informa Pharma Intelligence at booth 617 and Saama at booth 316 to learn more about the partnership.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

About Citeline
Citeline, part of Informa’s Pharma Intelligence vertical, is the world’s most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.

Citeline is the R&D Intelligence arm of Informa’s Pharma Intelligence vertical, one of the world’s leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets. For more information, visit pharmaintelligence.informa.com.

About Saama
Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. We are singularly focused on driving fast, flexible, impactful business outcomes for our clients through data and analytics. Our unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and big data technologies. We integrate manual and disconnected initiatives into a well-aligned roadmap facilitating the client’s journey from strategy through solution implementation.

About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Accolade Logo.jpg
Seattle, WA (July 1, 2020) - Accolade, Inc. ("Accolade"), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the pricing of its initial public offering of 10,022,726 shares of its common stock at a price to the public of $22.00 per share. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol "ACCD" on July 2, 2020, and the offering is expected to close on July 7, 2020, subject to customary closing conditions. In addition, Accolade has granted the underwriters a 30-day option to purchase up to 1,503,408 additional shares of common stock at the initial public offering price less the underwriting discount and commissions.
July 1, 2020
Mavenlink Logo.jpg
Irvine, CA (June 30, 2020) -- Mavenlink, the leading provider of cloud-based software for the modern services organization, today announced Steve DeSantis has joined its executive team as CFO to oversee essential business functions, guide organizational growth, and ensure Mavenlink continues to help professional services companies realize their full potential.
June 30, 2020
Carrick Logo TM.jpg
Technical Bootcamp To Continue Focus on Substantial Reskilling and Upskilling Labor Market Opportunity
June 30, 2020